

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

8th July 2026

Company:	Chordia Therapeutics Inc
Representative:	Chief Executive Officer Hiroshi Miyake (Security Code: 190A TSE Growth Market)
Contact:	IR Manager Ami Kira
MAIL:	info@chordiatherapeutics.com

Participation in BIO Asia–Taiwan 2026

Chordia Therapeutics Inc (Head Office: Fujisawa City, Kanagawa Prefecture; CEO: Hiroshi Miyake, “Chordia”) is pleased to announce that Hiroshi Miyake, Representative Director, will participate as a speaker at the Investment Summit, one of the programs of BIO Asia–Taiwan 2026, to be held in Taiwan on July 15, 2026. BIO Asia–Taiwan is one of Asia’s leading international conferences for the biotechnology and pharmaceutical industries, bringing together pharmaceutical companies, biotechnology companies, investors, and research institutions to exchange information and explore opportunities for research collaboration, business development, and networking.

At the event, Chordia will present its research and development pipeline and business strategy, while continuing its business development activities aimed at creating partnering opportunities for its pipeline programs, including the MALT1 inhibitor ocipumaltib.

Event Overview

Date	July 15 (Wed.) – July 19 (Sun.), 2026 (Presentation Session: B-1 Session, July 15, 15:10 – 17:20)
Venue	Room 701AB, 7F, TaiNEX 2, Taipei, Taiwan
URL	BIO Asia–Taiwan 2026

About Chordia Therapeutics

Chordia Therapeutics is a research and development-stage biopharmaceutical company specializing in oncology with clinical-stage assets, headquartered in Fujisawa City, Kanagawa Prefecture. Chordia’s lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. Rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research and development of several assets, including ocipumaltib (MALT1 inhibitor CTX-177), CTX-439, a CDK12 inhibitor, and GCN2 inhibitors. For more information, please visit our website <https://www.chordiatherapeutics.com/en/>.